Mr imaging of the liver with gd-bopta: Quantitative analysis of t1- weighted images at two different doses

Journal of Magnetic Resonance Imaging

Volumn 10, Issue 1, 1999, Pages 80-83

  Schima, Wolfgang ^b   Saini, Sanjay ^a   Petersein, Jan ^b   Weissleder, Ralph ^b   Harisinghani, Mukesh ^b   Mayo Smith, William ^b   Hahn, Peter F ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ELECTRON SPIN RESONANCE; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; LIVER DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL NOISE RATIO;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; SENSITIVITY AND SPECIFICITY;

EID: 0032793515     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199907)10:1<80::AID-JMRI11>3.0.CO;2-S     Document Type: Article

References (13)

1. Vogl TJ, Pegion W, McMahon C, et al. Gadobenate dimeglumine - a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR 1992;158;887-892.
2. de Haen C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 1993;3:179-186.
3. Kreft BP, Tanimoto A, Stark DD, et al. Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats. J Magn Reson Imaging 1993; 3:41-49.
4. Mirowitz SA, Lee JK, Brown JJ, et al. Rapid acquisition spin-echo (RASE) MR imaging: a new technique for reduction of artifacts and acquisition time. Radiology 1990;175;131-135.
5. Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996;200:785-792
6. Rosati G, Pirovano G, Spinazzi A. Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 1994;29(suppl 2):S183-185
7. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 1997;205:721-728.
8. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology 1996;199:513-520.
9. Mukamichi T, Baron RL, Peterson MS, Oliver JH, et al. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium. Radiology 1996;200:69-77.
10. Mahfouz AE, Hamm B, Wolf KJ, et al. Peripheral washout: a sign of malignancy on dynamic-enhanced MR images of focal liver lesions. Radiology 1994;190:49-52.
11. Gabata T, Matsui O, Kadoya M, et al. Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdominal Imaging 1998;26:309-313.
12. Miller WJ, Baron RL, Dodd GD III, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity in 200 consecutive transplant patients. Radiology 1994;193:645-650.
13. Manfredi R, Maresca G, Baron RL, et al. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 1998;8:862-867.